News Autolus closes on EU okay for leukaemia cell therapy The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.
News Merck agrees $3.9 billion takeover of SpringWorks Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.
News Merck puts a price on its SpringWorks takeover bid Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.
News With Merck circling, SpringWorks gets new drug approval Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.
News Merck confirms its interest in buying SpringWorks Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.
News FDA okays first therapy for desmoid tumours from SpringWorks Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face